Cited 3 time in
Identification and Functional Characterization of Anti-metastasis and Anti-angiogenic Activities of Triethylene Glycol Derivatives
| DC Field | Value | Language |
|---|---|---|
| dc.contributor.author | Oh, Eonju | - |
| dc.contributor.author | Garg, Sukant | - |
| dc.contributor.author | Liu, Ye | - |
| dc.contributor.author | Afzal, Sajal | - |
| dc.contributor.author | Gao, Ran | - |
| dc.contributor.author | Yun, Chae-Ok | - |
| dc.contributor.author | Kaul, Sunil C. | - |
| dc.contributor.author | Wadhwa, Renu | - |
| dc.date.accessioned | 2021-07-30T05:24:31Z | - |
| dc.date.available | 2021-07-30T05:24:31Z | - |
| dc.date.created | 2021-05-12 | - |
| dc.date.issued | 2018-11 | - |
| dc.identifier.issn | 2234-943X | - |
| dc.identifier.uri | https://scholarworks.bwise.kr/hanyang/handle/2021.sw.hanyang/4662 | - |
| dc.description.abstract | We had previously reported anticancer activity in the water extract (WEX) of Ashwagandha leaves, and identified Triethylene glycol (TEG) as an active tumor suppressor component. In this study, we investigated anti-migratory and anti-angiogenesis activities of WEX and TEG. We conducted in vitro and in vivo experiments using TEG, and its two derivatives, Triethyleneglycol dimethacrylate (TD-10), and Tetraethyleneglycol dimethacrylate (TD-11). The data revealed strong anticancer and anti-metastasis potentials in the derivatives. Non-toxic, anti-migratory doses of the derivatives showed inhibition of canonical Wnt/beta-catenin axis and consequent downregulation of EMT-signaling proteins (Vimentin, MMPs and VEGF). These results endorse that the TD-10 and TD-11 have potential to safely put a check on the aggressiveness of the metastatic cells and therefore represent promising candidates for the treatment of metastatic cancers. | - |
| dc.language | 영어 | - |
| dc.language.iso | en | - |
| dc.publisher | FRONTIERS MEDIA SA | - |
| dc.title | Identification and Functional Characterization of Anti-metastasis and Anti-angiogenic Activities of Triethylene Glycol Derivatives | - |
| dc.type | Article | - |
| dc.contributor.affiliatedAuthor | Yun, Chae-Ok | - |
| dc.identifier.doi | 10.3389/fonc.2018.00552 | - |
| dc.identifier.scopusid | 2-s2.0-85063294734 | - |
| dc.identifier.wosid | 000451635900001 | - |
| dc.identifier.bibliographicCitation | FRONTIERS IN ONCOLOGY, v.8 | - |
| dc.relation.isPartOf | FRONTIERS IN ONCOLOGY | - |
| dc.citation.title | FRONTIERS IN ONCOLOGY | - |
| dc.citation.volume | 8 | - |
| dc.type.rims | ART | - |
| dc.type.docType | Article | - |
| dc.description.journalClass | 1 | - |
| dc.description.isOpenAccess | N | - |
| dc.description.journalRegisteredClass | scie | - |
| dc.description.journalRegisteredClass | scopus | - |
| dc.relation.journalResearchArea | Oncology | - |
| dc.relation.journalWebOfScienceCategory | Oncology | - |
| dc.subject.keywordPlus | HUMAN DENTAL-PULP | - |
| dc.subject.keywordPlus | CYCLOOXYGENASE-2 EXPRESSION | - |
| dc.subject.keywordPlus | STEROIDAL LACTONE | - |
| dc.subject.keywordPlus | CANCER-CELLS | - |
| dc.subject.keywordPlus | DIMETHACRYLATE | - |
| dc.subject.keywordPlus | WITHAFERIN | - |
| dc.subject.keywordPlus | ASHWAGANDHA | - |
| dc.subject.keywordPlus | TUMOR | - |
| dc.subject.keywordPlus | CONTRIBUTES | - |
| dc.subject.keywordPlus | VIMENTIN | - |
| dc.subject.keywordAuthor | Ashwagandha | - |
| dc.subject.keywordAuthor | TEG | - |
| dc.subject.keywordAuthor | TEG-derivatives | - |
| dc.subject.keywordAuthor | cell migration | - |
| dc.subject.keywordAuthor | invasion | - |
| dc.subject.keywordAuthor | metastasis | - |
| dc.subject.keywordAuthor | therapy | - |
| dc.identifier.url | https://www.frontiersin.org/articles/10.3389/fonc.2018.00552/full | - |
Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.
222, Wangsimni-ro, Seongdong-gu, Seoul, 04763, Korea+82-2-2220-1366
COPYRIGHT © 2024 HANYANG UNIVERSITY.
Certain data included herein are derived from the © Web of Science of Clarivate Analytics. All rights reserved.
You may not copy or re-distribute this material in whole or in part without the prior written consent of Clarivate Analytics.
